alexa
Reach Us +1-217-403-9671
Dissolution Testing For Generic Drugs: An FDA Perspective | 8242
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Dissolution testing for generic drugs: An FDA perspective

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Om Anand

ScientificTracks Abstracts: JBB

DOI: 10.4172/2153-2435.10000S4

Abstract
I n vitro dissolution testing is an important tool used for development and approval of generic dosage forms. Th e objective of this presentation is to summarize how dissolution testing is used for the approval of safe and eff ective generic drug products in the United States (US). Dissolution testing is routinely used for stability and quality control purposes for both oral and non-oral dosage forms. Th e dissolution method should be developed using an appropriate validated method depending on the dosage form. Th ere are several ways in which dissolution testing plays a pivotal role in regulatory decision-making. It may be used to waive in vivo bioequivalence (BE) study requirements, as BE documentation for Scale Up and Post Approval Changes (SUPAC), and to predict the potential for a modifi ed-release (MR) drug product to dose-dump if co-administered with alcoholic beverages. Th us, in vitro dissolution testing plays a major role in FDA?s eff orts to reduce the regulatory burden and unnecessary human studies in generic drug development without sacrifi cing the quality of the drug products
Biography
Om Anand, Ph.D., Division of Bioequivalence, OGD, CDER, FDA: Rockville, MD. Dr. Anand is a reviewer and dissolution focal point at Division of Bioequivalence-2, Of fi ce of Generic Drugs, CDER, FDA at Rockville, Maryland. He received his Bachelor in Pharmacy from the University of Delhi, India in 1997, and a Master in Pharmacy in 2000 from the Punjabi University Patiala, Punjab, India. He received his Doctorate in Pharmaceutical Sciences from the University of Tennessee, USA, in 2008. His Ph.D. research involved formulation and development of biodegradable injectable gels loaded with insulin. From 2000 to 2003, he worked in pharmaceutical industry as a formulation scientist and developed wide variety of modi fi ed-release solid oral dosage forms. Research interests have included Pharmacokinetics, Biopharmaceutics and in-vitro dissolution of poorly soluble drugs and in-vitro and in-vivo correlations. He has published several articles and has two patents on his name.
Top